The Michael J. Fox Foundation seeks applications that leverage and translate basic research in order to enable therapeutic development. To this end, MJFF believes that promoting target and pathway validation studies within academic and industry laboratories can bridge the critical gap between basic biology and therapeutic development.
The Target Advancement Program is open to industry and academic investigators proposing to build conclusive evidence to rationalize biological targets and pathways for Parkinson’s disease (PD) therapeutic development. Part of our Edmond J. Safra Core Programs for PD Research, this program will support projects focused on validating targets and defining pathways implicated in PD pathological processes and/or symptomology.
Applications should focus on studies that achieve one or more of the following goals:
- Demonstrate pathological relevance of a target by studying its altered expression, distribution, or function in PD-relevant human tissues.
- Demonstrate that modulation of the target or pathway in vivo in whole mammalian PD models using genetic or pharmacological manipulations yields outcomes predictive of clinical efficacy or relevance in human PD.
- Elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
- Replicate or further validate recently published, high-impact findings in PD biology.
Please note that MJFF has made significant investments in the biology of high-priority targets, including alpha-synuclein, LRRK2, GBA and Parkin/PINK1. Proposals focusing on these targets will be considered on a case-by-case basis and carefully evaluated against the existing MJFF portfolio.
Watch our informational webinar on-demand to learn more about our Foundation's funding strategy and opportunities, and the application and review processes. View Now.
Please note we made changes to our publication and indirect costs policies in early 2020. Review the updated Application Guidelines and the new open access publication policy for complete details. Contact email@example.com with questions about the RFA, application process or these policies.